Rani Therapeutics Holdings (RANI) has received a new Buy rating, initiated by H.C. Wainwright analyst, Brandon Folkes.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brandon Folkes has given his Buy rating due to a combination of factors that highlight Rani Therapeutics Holdings’ potential for growth and value creation. One of the primary reasons is the company’s innovative platform technology, the RaniPill, which has been validated through a significant collaboration with Chugai Pharmaceutical Co. This partnership not only underscores the potential of the RaniPill but also suggests that Rani’s technology could unlock substantial value, especially as the company pursues further collaborations.
Additionally, Rani is advancing its RT-114 program, which aims to introduce a first-in-class orally administered GLP-1/GLP-2 dual agonist for obesity. This development leverages the RaniPill platform to provide an effective oral alternative to injectable therapies. The promising preclinical results, which show comparable efficacy to existing treatments, further support the potential for Rani’s technology to achieve systemic delivery. These factors, combined with the anticipated data readouts on RT-114, are expected to drive near-term value for Rani’s shares, making it an attractive investment opportunity.
In another report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $10.00 price target.